Biotech · Public company · Princeton, NJ, US

Grace Therapeutics, Inc.

Ticker GRCE · SEC CIK 0001444192

Track this companyFree. Adds Grace Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials31 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline3

CaPrePhase 3 · HypertriglyceridemiaClinicalTrials.gov · fetched Nov 12, 2026
GTX-104Phase 3 · Aneurysmal Subarachnoid Hemorrhage (aSAH)ClinicalTrials.gov · fetched Nov 12, 2026
Nimotop 30 MG Oral CapsulePhase 3 · Aneurysmal Subarachnoid Hemorrhage (aSAH)ClinicalTrials.gov · fetched Nov 12, 2026

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAHPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 20, 2023ClinicalTrials.gov NCT05995405 · fetched Nov 12, 2026
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)PHASE3 · COMPLETED · started Feb 1, 2018ClinicalTrials.gov NCT03361501 · fetched Nov 12, 2026
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)PHASE3 · COMPLETED · started Jan 23, 2018ClinicalTrials.gov NCT03398005 · fetched Nov 12, 2026